Halaven

Type: Product
Name: Halaven
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Branded and Targeted Treatments Driving Almost $4 Billion Growth in Breast Cancer Therapeutics Market

Breast cancer therapeutics market value to grow from $9.2 billion in 2013 to $13.1 billion by 2020ReportstackThe increased use of targeted therapies, along with a greater uptake of branded drugs and rising incidence population, will cause the breast cancer ... [Published Pressat - Jul 23 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

Eisai's Halaven approved for earlier usage against breast cancer in EU

:27 in Pharmaceutical Company Product News Eisai has announced that the European Commission has approved its breast cancer therapy Halaven for use in an expanded indication. The decision will allow Halaven to be used in the earlier treatment of patients ... [Published Zenopa - Jul 10 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

Eisai receives EC approval for indication expansion of breast cancer treatment

Eisai Co., Ltd. has received European Commission, or EC, approval for the indication expansion of Halaven to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic ... [Published Individual.com - Jul 09 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

Top 100 Agencies 2014: Harrison and Star

Share this article:Balancing the status quo with a taste for the new reaps benefits Harrison and Star may have marked a victory of sorts for the status quo during Mardene Miller's first full year overseeing day-to-day operations at the agency—but that ... [Published Medical Marketing And Media - Jul 09 2014]
First reported Jul 07 2014 - Updated Jul 08 2014 - 1 reports

Lexicon Announces Appointment of Lonnel Coats as President and Chief Executive Officer

/PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lonnel Coats has been appointed president and chief executive officer effective July 7, 2014. Mr. Coats most recently served as president and chief executive officer of ... [Published BusinessWeek - Jul 07 2014]
First reported Jul 07 2014 - Updated Jul 08 2014 - 3 reports

Halaven (eribulin) Garners European Commission MAA for Advanced Breast Cancer After Only One Prior Chemotherapy

The European Commission (EC) has issued Marketing Authorisation Approval (MAA) for Halaven (eribulin) in the treatment of patients with locally advanced or metastatic breast cancer (MBC) who have progressed after at least one chemotherapeutic regimen ... [Published Individual.com - Jul 08 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

Expanded EU approval sets Halaven on course

| SCRIPThe new indication means that it can be used in patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline ... [Published BioPortfolio - Jul 03 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 3 reports

Eisai’s breast cancer drug Halaven receives MAA in Europe

The European Commission has issued Marketing Authorization Approval (MAA) for Halaven (eribulin) from Japanese drug major Eisai (TYO: 4523) in the treatment of patients with locally advanced or metastatic breast cancer (MBC) who have progressed after ... [Published Pharma Letter - Jul 03 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 1 reports

Breast Cancer Therapeutics Market Expands in Asia-Pacific, According to a New Study on ASDReports

ASDReports.com - Jun. 27, 2014 - AMSTERDAM, Netherlands -- Thanks to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics market value will climb from $1.5 billion in 2013 to $2.5 billion by 2020, at a ... [Published Prlog - Jun 27 2014]
First reported Jun 12 2014 - Updated Jun 12 2014 - 1 reports

Opinion/decision on a Paediatric Investigation Plan (PIP): Halaven, Eribulin, Therapeutic area: Oncology

Entities: Eribulin, Halaven, Oncology
First reported May 27 2014 - Updated May 27 2014 - 2 reports

Eisai's Halaven Eribulin Receives Positive CHMP Opinion for Advanced Breast Cancer After Only One Prior Chemotherapy

/PRNewswire/ -- FOREUMEDIA ONLY: NOT FOR SWISSMEDIA New indicationtobenefitthousands of women across Europe The European Medicines Agency's (EMA) Committee for Medi...Related Biotechnology, Pharmaceutical and Healthcare NewsOriginal Article: Eisai's Halaven ... [Published BioPortfolio - May 27 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 2 reports

Eisai announces availability of Halaven in Lebanon for treatment of metastatic breast cancer

Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania) has announces that Halaven (eribulin) is now commercially available in Lebanon as a treatment for women with locally advanced or metastatic breast cancer who have previously received at lea ... [Published BioPortfolio - Apr 07 2014]

Quotes

...The company said this comes as part of its ongoing efforts to "make further contributions to address the diversified needs of, and increase the benefits provided to, patients with cancer and their families, as well as healthcare providers" . Halaven was the first single-agent chemotherapy agent to be shown to statistically and significantly extend overall survival rates among metastatic...
...(35 percent vs 4 percent), leukopenia (31 percent vs 10 percent), diarrhoea (14 vs 29 percent) and nausea (22 percent vs 24 percent), respectively. "Eisai is very pleased that eribulin is now indicated for use in women with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. This earlier use of eribulin will allow more women across Europe to receive the survival benefits that treatment with eribulin may provide. As a company, we continue to be committed to broadening access to eribulin to help redress the inequality between early and advanced breast cancer outcomes" said Gary Hendler, President Eisai Global Oncology Business Unit
...from Eisai, I had the privilege to be presented with many new opportunities to continue contributing to our great industry," said Lonnel Coats. "By far, Lexicon is the most exciting and promising opportunity I reviewed. Lexicon is on the cusp of becoming a major contributor to improving the lives of patients living with type 1 and 2 diabetes, with carcinoid syndrome and with many other conditions. We have much work to do before we achieve all of our goals, but I am enthusiastic and energized at our prospects. I am honored to have the trust of the board of directors and management to lead Lexicon through the next phase of its evolution."
Original Article: NEXT ARTICLE More From BioPortfolio on "Eisai gets EC approval of indication expansion for Halaven to treat breast cancer"

More Content

All (32) | News (27) | Reports (0) | Blogs (5) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Eisai:R&I Affirms AA-/a-1+,Changes Outlook to N... [Published Noodls - Jul 28 2014]
Branded and Targeted Treatments Driving Almost ... [Published Samedan Ltd Pharmaceutical Publishers - Jul 23 2014]
Branded and Targeted Treatments Driving Almost ... [Published Pressat - Jul 23 2014]
Eisai's Halaven approved for earlier usage agai... [Published Zenopa - Jul 10 2014]
Ado-Trastuzumab Emtansine Improves Progression-... [Published The ASCO Post - Jul 09 2014]
Eisai receives EC approval for indication expan... [Published Individual.com - Jul 09 2014]
Top 100 Agencies 2014: Harrison and Star [Published Medical Marketing And Media - Jul 09 2014]
Halaven (eribulin) Garners European Commission ... [Published Individual.com - Jul 08 2014]
Lexicon Announces Appointment of Lonnel Coats a... [Published BusinessWeek - Jul 07 2014]
Eisai gets EC approval of indication expansion ... [Published BioPortfolio - Jul 07 2014]
Eisai gets EC approval of indication expansion ... [Published PBR - News - Jul 07 2014]
Life-extending treatment for metastatic breast ... [Published Medical News Today - Jul 04 2014]
Expanded EU approval sets Halaven on course [Published BioPortfolio - Jul 03 2014]
Eisai’s breast cancer drug Halaven receives MAA... [Published Pharma Letter - Jul 03 2014]
Eisais breast cancer drug Halaven receives MAA ... [Published BioPortfolio - Jul 03 2014]
Halaven® (eribulin) Receives European Commissio... [Published OSIX News - Jul 03 2014]
Breast Cancer Therapeutics Market Expands in As... [Published Prlog - Jun 27 2014]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Jun 12 2014]
Eisai's Halaven Eribulin Receives Positive CHMP... [Published BioPortfolio - May 27 2014]
Eisai Receives Positive Opinion from EMA's CHMP... [Published BioPortfolio - May 27 2014]
Pending EC decision: Halaven, eribulin, Opinion... [Published Pending EC decisions and European Public Assess ... - May 23 2014]
Eisai announces availability of Halaven in Leba... [Published BioPortfolio - Apr 07 2014]
Eisai announces availability of Halaven in Leba... [Published PBR - News - Apr 07 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 07 2014]
Eisai's lenvatinib to follow in Nexavar's foots... [Published BioPortfolio - Feb 04 2014]
The Pixie Awards Announces 2014 Competition Win... [Published PRWeb - Jan 23 2014]
Halaven Plus Herceptin Winning Combo CMECE [Published BioPortfolio - Dec 16 2013]
Eisai Oncology to Present Data Analyses on Hala... [Published BioPortfolio - Dec 05 2013]
Eisai to Present New Research on Halaven Eribul... [Published BioPortfolio - Dec 05 2013]
Newbridge to market Eisai's breast cancer treat... [Published Pharmaceutical Business Review - Nov 18 2013]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Eisai gets EC approval of indication expansion ... [Published PBR - News - Jul 07 2014]
Japanese pharmaceutical firm Eisai has received approval from the European Commission (EC) of the indication expansion of Halaven (eribulin mesylate) to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who ...
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Jun 12 2014]
Pending EC decision: Halaven, eribulin, Opinion... [Published Pending EC decisions and European Public Assess ... - May 23 2014]
Eisai announces availability of Halaven in Leba... [Published PBR - News - Apr 07 2014]
Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania) has announces that Halaven (eribulin) is now commercially available in Lebanon as a treatment for women with locally advanced or metastatic breast cancer who have previously received at least ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 07 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.